NCT06052163 · Phase 2 · RECRUITING
Bumetanide in Patients With Alzheimer's Disease
This Phase 2 trial is testing bumetanide — a common water pill already FDA-approved for fluid retention and high blood pressure — as a potential treatment for Alzheimer's disease. Researchers want to know if it is safe and tolerable for people with confirmed AD, and whether it affects cognitive or biological markers of the disease. Phase 2 means they are exploring effectiveness and safety, not yet proving it works.
You may qualify if
- Mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Alzheimer's disease medications are planned to remain stable throughout.
- Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI.
You're excluded if
- Clinically significant abnormalities in screening laboratory tests
- Chronic liver disease
- Renal insufficiency
- Poorly managed hypertension
- Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-01-14